English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Liposomal amphotericin B (L-AMB) is reported in Japan to be less effective and not as safe for treating severe fungal infections in non-neutropenic patients as in neutropenic patients. Therefore, we evaluated the clinical ef cacy and safety of L-AMB as an antifungal agent in non-neutropenic patients. The ef cacy of L-AMB administered intravenously in patients with severe fungal infections was retrospectively investigated by reviewing medical records from November 2007 to July 2010. The records of 18 eligible adult patients were analyzed according to the L-AMB dose they received : standard (2.5 mg / kg / day ; n=5) and high (> 2.5 mg / kg / day ; n=13). The average age of the standardand high-dosage group was 71.4 and 60.3 years, respectively. The 30-day survival rate in the standardand high-dosage group was 20% (n=1) and 76.9% (n=10), respectively (P=0.047). A signi cant antipyretic effect was observed in the high-dosage group (P=0.001). There was no relationship between the dosage of L-AMB and any side effect. By carrying out the treatment according to the information provided at the time of administration, no cases were discontinued because of side effects. A high dosage of L-AMB is more effective than the standard dosage and both dosages are welltolerated in non-neutropenic patients.

Clinical Study of the Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Fungal Infections in Non-neutropenic Patients